-
2010 - 2013
Incorporated, and Growth
Scaffold Established -
2014 - 2017
Foundation of
R&D Established -
2018 - 2021
Growth Momentum
Secured
-
2013.05
Entered into a Technology Transfer Agreement with YD Global Life Science of Agent Treating Chemotherapy Induced Peripheral Neuropathy
-
2013.02
Entered into a Technology License Agreement with S&D CO., Ltd of Material for Controlling Blood Glucose Following Food Consumption
-
2011.01
Obtained Certification of Venture Company By KIBO (R&D Company)
-
2010.03
FRONTBIO Inc. Incorporated.
-
2017.10
Obtained Patent Registration of Composition for Prevention or Treatment of Diabetes Complication, and the Patent Transferred to Hallym University
-
2017.05
Obtained Registration of Patent of Composition for Prevention or Treatment of Diabetes Complication, and the Patent Transferred to Hallym University
-
2016.11
Entered into a Patent License Agreement with Hallym University of Composition for Inhibiting Diabetic Renal Fibrosis Comprising FB700
-
2016.05
Changed the Address of Head office to 32, Soyanggang-ro, Chuncheon-si, Gangwon-do
-
2016.04
Obtained Certification of R&D Center By KOITA
-
2014.03
Obtained Registration of Patent of Composition for Prevention or Treatment of Diabetes Complication Comprising Decaffeoyl Quinic Acid Derivatives
-
2021.01
Changed the Address of Head office to #301~302, Bio.#2, 32 Soyanggang-ro, Chuncheon-si, Gangwon-do
-
2021.01
Eczema therapeutics(FB700) clinical phase1 IND approval
-
2020.07
Performed FB300 Nonclinical Study
-
2020.01
Applied for Patent Registration of Pharmaceutical Composition for Preventing or Treating Cancer Comprising Complex of FB300-A and FB301-B Derivatives as Active Ingredients
-
2019.12
Opened Seoul Branch Office with the address of Samseong-dong , Gangnam-gu, Seoul
-
2019.05
Obtained Registration of Patent of Pharmaceutical Composition for Preventing or Treating Cancer Comprising FB300-A and FB302-B.
-
2018.10
Obtained Registration of Patent Pharmaceutical Composition for Preventing or Treating Diabetic Neuropathic Pain Comprising FB100 or its Pharmaceutically Acceptable Salts as Active Ingredients, and the Patent Transferred to Hallym University
-
2018.03
Obtained Patent Registration of Pharmaceutical Composition for Preventing or Treating Skin Disease Comprising FB700